細胞・遺伝子治療のバイオ製造CDMO市場：構成要素、フェーズ、適応症別-2025-2030年の世界予測

細胞・遺伝子治療のバイオ製造CDMO市場は、2023年に3億3,812万米ドルと評価され、2024年には4億8,547万米ドルに達すると予測され、CAGR 32.53％で成長し、2030年には24億2,890万米ドルに達すると予測されています。

細胞・遺伝子治療バイオマニュファクチャリング開発・製造受託機関（CDMO）は、遺伝子疾患やがんをターゲットとした高度な個別化治療のオーダーメイド生産に重点を置く、バイオ医薬品業界における重要なセグメントです。この市場セグメントは、慢性疾患の有病率の増加、CRISPRのような遺伝子編集技術の進歩、バイオテクノロジー研究開発への投資の増加によって牽引されています。CDMOの必要性は、細胞治療や遺伝子治療の生産が複雑で資源集約的であることに起因しており、専門施設、技術的専門知識、厳格な規制基準の遵守が求められます。これらの治療法の用途は、がん治療、希少遺伝性疾患、再生医療など多岐にわたり、最終用途は主に病院、研究機関、バイオテクノロジー企業です。主な成長促進要因としては、規制機関による細胞・遺伝子治療の承認率の上昇、製造プロセスにおける技術進歩、公的・民間資金の増加などが挙げられます。潜在的なビジネスチャンスは、バイオテクノロジー企業とのパートナーシップの拡大、自動化やAIによる製造能力の強化、需要増に対応した生産規模の拡大などにあります。企業への調査提案としては、最先端設備への投資、熟練労働者の育成、継続的イノベーションのための研究機関との連携などがあります。しかし、市場の拡大は、製造コストの高さ、治療提供における物流の課題、規制上の障壁によって制約を受けています。さらに、治療薬のコストが高いため、患者がすぐに治療を受けられる環境には限界があり、遺伝子組み換えに関する倫理的な懸念が、より広範な受容を遅らせる可能性もあります。技術革新が必要とされる分野には、費用対効果の高い生産戦略の開発、サプライチェーン・ロジスティクスの改善、新規治療応用の発見などがあります。同種療法に関する調査や遺伝子編集技術の精度向上により、生産が効率化され、コストが削減される可能性があります。市場は急速な進化を特徴としており、新たな動向を活用し、既存の課題を効果的に克服するためには、機敏な戦略と適応力のあるビジネスモデルが必要となります。

市場力学：急速に進化する細胞・遺伝子治療のバイオ製造CDMO市場の主要市場インサイトを公開

細胞・遺伝子治療のバイオ製造CDMO市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的意思決定、新たなビジネスチャンスの獲得を行うことができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができるとともに、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 細胞工学・遺伝子工学・治療法の研究開発活動の増加
  • 慢性疾患や遺伝性疾患を治療するための遺伝子治療に対するニーズの高まり
  • CDMOと大手企業との協業活動の増加
• 市場抑制要因
  • CDMOサービスのコスト高
• 市場機会
  • CDMOによるデジタル化とAI技術の導入への取り組み
  • バイオテクノロジーおよび医薬品新興企業の増加
• 市場の課題
  • 遺伝子・細胞研究を取り巻く複雑な規制

ポーターのファイブフォース：細胞・遺伝子治療のバイオ製造CDMO市場をナビゲートする戦略ツール

ポーターのファイブフォースフレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することで、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：細胞・遺伝子治療のバイオ製造CDMO市場における外部からの影響の把握

外部マクロ環境要因は、細胞・遺伝子治療のバイオ製造CDMO市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析細胞・遺伝子治療のバイオ製造CDMO市場における競合情勢の把握

細胞・遺伝子治療のバイオ製造CDMO市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックス細胞・遺伝子治療のバイオ製造CDMO市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、細胞・遺伝子治療のバイオ製造CDMO市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によってベンダーを明確かつ正確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨細胞・遺伝子治療のバイオ製造CDMO市場における成功への道筋を描く

細胞・遺伝子治療のバイオ製造CDMO市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を見直すことで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています：

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 細胞工学、遺伝子工学、治療法の研究開発活動の増加
    • 慢性疾患や遺伝性疾患を治療するための遺伝子治療の必要性が高まっている
    • CDMOと大手企業間の協力活動の増加
  • 抑制要因
    • CDMOサービスの高コスト
  • 機会
    • CDMOによるデジタル化・AI技術の導入に向けた取り組み
    • バイオテクノロジーと製薬の新興企業の増加
  • 課題
    • 遺伝子・細胞調査を取り巻く複雑な規制
• 市場セグメンテーション分析
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 細胞・遺伝子治療のバイオ製造CDMO市場：コンポーネント別

• 細胞療法
• プラスミドDNA
• ウイルスベクター

第7章 細胞・遺伝子治療のバイオ製造CDMO市場フェーズ別

• フェーズ1
• フェーズ2
• フェーズ3
• フェーズ4

第8章 細胞・遺伝子治療のバイオ製造CDMO市場適応症別

• がん
• 心血管疾患
• 遺伝性疾患
• 感染症
• 神経疾患

第9章 南北アメリカの細胞・遺伝子治療のバイオ製造CDMO市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第10章 アジア太平洋地域の細胞・遺伝子治療のバイオ製造CDMO市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第11章 欧州・中東・アフリカの細胞・遺伝子治療のバイオ製造CDMO市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第12章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• AGC Biologics
• Almac Group
• Becton, Dickinson and Company
• Bio-Rad Laboratories, Inc.
• Bio-Techne Corporation
• Catalent Inc.,
• Charles River Laboratories International Inc.
• Danaher Corporation
• Endress+Hauser Group Services AG
• FUJIFILM Diosynth Biotechnologies
• GC Corporation
• General Electric Company
• Getinge AB
• Infors AG
• Lonza Group Ltd
• Merck KGaA
• Miltenyi Biotec B.V. & Co. KG
• Patheon Inc.
• PCI Pharma Services
• Pfizer CentreOne
• PIERRE GUERIN
• Recipharm AB
• Samsung Biologics
• Sartorius AG
• Thermo Fisher Scientific
• uBriGene
• WuXi Advanced Therapies
• WuXi AppTec

LIST OF FIGURES

• FIGURE 1. CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET RESEARCH PROCESS
• FIGURE 2. CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COMPONENT, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COMPONENT, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PHASE, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PHASE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. AMERICAS CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 13. AMERICAS CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. UNITED STATES CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 15. UNITED STATES CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. ASIA-PACIFIC CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 17. ASIA-PACIFIC CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 19. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 21. CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET DYNAMICS
• TABLE 7. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY CELL THERAPY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PLASMID DNA, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY VIRAL VECTOR, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PHASE 1, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PHASE 2, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PHASE 3, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PHASE 4, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY CANCER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY CARDIOVASCULAR DISEASE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY GENETIC DISORDERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY INFECTIOUS DISEASE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 22. AMERICAS CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 23. AMERICAS CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 24. AMERICAS CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 25. AMERICAS CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 26. ARGENTINA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 27. ARGENTINA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 28. ARGENTINA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 29. BRAZIL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 30. BRAZIL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 31. BRAZIL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 32. CANADA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 33. CANADA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 34. CANADA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 35. MEXICO CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 36. MEXICO CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 37. MEXICO CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 38. UNITED STATES CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 39. UNITED STATES CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 40. UNITED STATES CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 41. UNITED STATES CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 42. ASIA-PACIFIC CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 43. ASIA-PACIFIC CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 44. ASIA-PACIFIC CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 45. ASIA-PACIFIC CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 46. AUSTRALIA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 47. AUSTRALIA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 48. AUSTRALIA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 49. CHINA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 50. CHINA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 51. CHINA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 52. INDIA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 53. INDIA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 54. INDIA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 55. INDONESIA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 56. INDONESIA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 57. INDONESIA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 58. JAPAN CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 59. JAPAN CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 60. JAPAN CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 61. MALAYSIA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 62. MALAYSIA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 63. MALAYSIA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 64. PHILIPPINES CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 65. PHILIPPINES CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 66. PHILIPPINES CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 67. SINGAPORE CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 68. SINGAPORE CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 69. SINGAPORE CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 70. SOUTH KOREA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 71. SOUTH KOREA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 72. SOUTH KOREA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 73. TAIWAN CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 74. TAIWAN CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 75. TAIWAN CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 76. THAILAND CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 77. THAILAND CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 78. THAILAND CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 79. VIETNAM CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 80. VIETNAM CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 81. VIETNAM CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 82. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 83. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 84. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 85. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 86. DENMARK CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 87. DENMARK CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 88. DENMARK CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 89. EGYPT CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 90. EGYPT CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 91. EGYPT CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 92. FINLAND CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 93. FINLAND CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 94. FINLAND CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 95. FRANCE CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 96. FRANCE CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 97. FRANCE CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 98. GERMANY CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 99. GERMANY CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 100. GERMANY CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 101. ISRAEL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 102. ISRAEL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 103. ISRAEL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 104. ITALY CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 105. ITALY CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 106. ITALY CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 107. NETHERLANDS CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 108. NETHERLANDS CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 109. NETHERLANDS CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 110. NIGERIA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 111. NIGERIA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 112. NIGERIA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 113. NORWAY CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 114. NORWAY CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 115. NORWAY CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 116. POLAND CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 117. POLAND CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 118. POLAND CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 119. QATAR CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 120. QATAR CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 121. QATAR CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 122. RUSSIA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 123. RUSSIA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 124. RUSSIA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 125. SAUDI ARABIA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 126. SAUDI ARABIA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 127. SAUDI ARABIA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 128. SOUTH AFRICA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 129. SOUTH AFRICA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 130. SOUTH AFRICA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 131. SPAIN CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 132. SPAIN CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 133. SPAIN CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 134. SWEDEN CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 135. SWEDEN CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 136. SWEDEN CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 137. SWITZERLAND CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 138. SWITZERLAND CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 139. SWITZERLAND CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 140. TURKEY CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 141. TURKEY CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 142. TURKEY CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 143. UNITED ARAB EMIRATES CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 144. UNITED ARAB EMIRATES CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 145. UNITED ARAB EMIRATES CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 146. UNITED KINGDOM CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 147. UNITED KINGDOM CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 148. UNITED KINGDOM CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 149. CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 150. CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET, FPNV POSITIONING MATRIX, 2023

The Cell & Gene Therapy Biomanufacturing CDMO Market was valued at USD 338.12 million in 2023, expected to reach USD 485.47 million in 2024, and is projected to grow at a CAGR of 32.53%, to USD 2,428.90 million by 2030.

Cell and gene therapy biomanufacturing Contract Development and Manufacturing Organizations (CDMOs) represent a crucial segment in the biopharmaceutical industry, focusing on the bespoke production of advanced, personalized therapies targeting genetic diseases and cancers. This market segment is driven by the increasing prevalence of chronic diseases, advancements in gene editing technologies like CRISPR, and growing investments in biotech research and development. The necessity of CDMOs stems from the complex and resource-intensive nature of cell and gene therapy production, which requires specialized facilities, technical expertise, and compliance with stringent regulatory standards. Applications of these therapies are vast, spanning cancer treatment, rare genetic disorders, and regenerative medicine, with end-use primarily in hospitals, research institutes, and biotech companies. Key growth drivers include the rising approval rates of cell and gene therapies by regulatory bodies, technological advancements in manufacturing processes, and increasing public and private funding. Potential opportunities lie in expanding partnerships with biotech firms, enhancing manufacturing capabilities with automation and AI, and scaling production to meet increasing demand. Recommendations for companies include investing in state-of-the-art facilities, training a skilled workforce, and collaborating with research institutions for continuous innovation. However, market expansion is constrained by high production costs, logistical challenges in therapy delivery, and regulatory barriers. Furthermore, the high cost of therapies limits immediate patient accessibility, while ethical concerns regarding genetic modification may delay broader acceptance. Areas ripe for innovation include developing cost-effective production strategies, improving supply chain logistics, and discovering novel therapeutic applications. Research into allogeneic therapies and improving the precision of gene editing technologies could streamline production and lower costs. The market is characterized by rapid evolution, necessitating agile strategies and adaptive business models to leverage emerging trends and overcome existing challenges effectively.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Cell & Gene Therapy Biomanufacturing CDMO Market

The Cell & Gene Therapy Biomanufacturing CDMO Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Growing number of R&D activities in cellular and genetic engineering and therapies
  • Increasing need for genetic treatments to cure chronic and genetic disorders
  • Rising number of collaborative activities between CDMOs and major players
• Market Restraints
  • High cost of CDMO services
• Market Opportunities
  • Efforts by CDMOs to incorporate digitalization and AI technologies
  • Rising number of biotechnology and pharmaceutical startups
• Market Challenges
  • Complex regulations surrounding genetic and cell research

Porter's Five Forces: A Strategic Tool for Navigating the Cell & Gene Therapy Biomanufacturing CDMO Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Cell & Gene Therapy Biomanufacturing CDMO Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Cell & Gene Therapy Biomanufacturing CDMO Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Cell & Gene Therapy Biomanufacturing CDMO Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Cell & Gene Therapy Biomanufacturing CDMO Market

A detailed market share analysis in the Cell & Gene Therapy Biomanufacturing CDMO Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Cell & Gene Therapy Biomanufacturing CDMO Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Cell & Gene Therapy Biomanufacturing CDMO Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Cell & Gene Therapy Biomanufacturing CDMO Market

A strategic analysis of the Cell & Gene Therapy Biomanufacturing CDMO Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Cell & Gene Therapy Biomanufacturing CDMO Market, highlighting leading vendors and their innovative profiles. These include AGC Biologics, Almac Group, Becton, Dickinson and Company, Bio-Rad Laboratories, Inc., Bio-Techne Corporation, Catalent Inc.,, Charles River Laboratories International Inc., Danaher Corporation, Endress+Hauser Group Services AG, FUJIFILM Diosynth Biotechnologies, GC Corporation, General Electric Company, Getinge AB, Infors AG, Lonza Group Ltd, Merck KGaA, Miltenyi Biotec B.V. & Co. KG, Patheon Inc., PCI Pharma Services, Pfizer CentreOne, PIERRE GUERIN, Recipharm AB, Samsung Biologics, Sartorius AG, Thermo Fisher Scientific, uBriGene, WuXi Advanced Therapies, and WuXi AppTec.

Market Segmentation & Coverage

This research report categorizes the Cell & Gene Therapy Biomanufacturing CDMO Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Component, market is studied across Cell Therapy, Plasmid DNA, and Viral Vector.
• Based on Phase, market is studied across Phase 1, Phase 2, Phase 3, and Phase 4.
• Based on Indication, market is studied across Cancer, Cardiovascular Disease, Genetic Disorders, Infectious Disease, and Neurological Disorders.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Growing number of R&D activities in cellular and genetic engineering and therapies
    • 5.1.1.2. Increasing need for genetic treatments to cure chronic and genetic disorders
    • 5.1.1.3. Rising number of collaborative activities between CDMOs and major players
  • 5.1.2. Restraints
    • 5.1.2.1. High cost of CDMO services
  • 5.1.3. Opportunities
    • 5.1.3.1. Efforts by CDMOs to incorporate digitalization and AI technologies
    • 5.1.3.2. Rising number of biotechnology and pharmaceutical startups
  • 5.1.4. Challenges
    • 5.1.4.1. Complex regulations surrounding genetic and cell research
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Cell & Gene Therapy Biomanufacturing CDMO Market, by Component

• 6.1. Introduction
• 6.2. Cell Therapy
• 6.3. Plasmid DNA
• 6.4. Viral Vector

7. Cell & Gene Therapy Biomanufacturing CDMO Market, by Phase

• 7.1. Introduction
• 7.2. Phase 1
• 7.3. Phase 2
• 7.4. Phase 3
• 7.5. Phase 4

8. Cell & Gene Therapy Biomanufacturing CDMO Market, by Indication

• 8.1. Introduction
• 8.2. Cancer
• 8.3. Cardiovascular Disease
• 8.4. Genetic Disorders
• 8.5. Infectious Disease
• 8.6. Neurological Disorders

9. Americas Cell & Gene Therapy Biomanufacturing CDMO Market

• 9.1. Introduction
• 9.2. Argentina
• 9.3. Brazil
• 9.4. Canada
• 9.5. Mexico
• 9.6. United States

10. Asia-Pacific Cell & Gene Therapy Biomanufacturing CDMO Market

• 10.1. Introduction
• 10.2. Australia
• 10.3. China
• 10.4. India
• 10.5. Indonesia
• 10.6. Japan
• 10.7. Malaysia
• 10.8. Philippines
• 10.9. Singapore
• 10.10. South Korea
• 10.11. Taiwan
• 10.12. Thailand
• 10.13. Vietnam

11. Europe, Middle East & Africa Cell & Gene Therapy Biomanufacturing CDMO Market

• 11.1. Introduction
• 11.2. Denmark
• 11.3. Egypt
• 11.4. Finland
• 11.5. France
• 11.6. Germany
• 11.7. Israel
• 11.8. Italy
• 11.9. Netherlands
• 11.10. Nigeria
• 11.11. Norway
• 11.12. Poland
• 11.13. Qatar
• 11.14. Russia
• 11.15. Saudi Arabia
• 11.16. South Africa
• 11.17. Spain
• 11.18. Sweden
• 11.19. Switzerland
• 11.20. Turkey
• 11.21. United Arab Emirates
• 11.22. United Kingdom

12. Competitive Landscape

• 12.1. Market Share Analysis, 2023
• 12.2. FPNV Positioning Matrix, 2023
• 12.3. Competitive Scenario Analysis
• 12.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. AGC Biologics
• 2. Almac Group
• 3. Becton, Dickinson and Company
• 4. Bio-Rad Laboratories, Inc.
• 5. Bio-Techne Corporation
• 6. Catalent Inc.,
• 7. Charles River Laboratories International Inc.
• 8. Danaher Corporation
• 9. Endress+Hauser Group Services AG
• 10. FUJIFILM Diosynth Biotechnologies
• 11. GC Corporation
• 12. General Electric Company
• 13. Getinge AB
• 14. Infors AG
• 15. Lonza Group Ltd
• 16. Merck KGaA
• 17. Miltenyi Biotec B.V. & Co. KG
• 18. Patheon Inc.
• 19. PCI Pharma Services
• 20. Pfizer CentreOne
• 21. PIERRE GUERIN
• 22. Recipharm AB
• 23. Samsung Biologics
• 24. Sartorius AG
• 25. Thermo Fisher Scientific
• 26. uBriGene
• 27. WuXi Advanced Therapies
• 28. WuXi AppTec